3 results
Primary: To demonstrate the efficacy of QGE031 relative to placebo at 12 weeks in patients withatopic dermatitis (AD) as assessed by Eczema Area and Severity Index (EASI).Secondary: efficacy assessed by Investigator Global Assessment (IGA, 12 weeks…
Primary:• To compare overall survival (OS) in patientsrandomized to NGR-hTNF plus BIC versuspatients randomized to placebo plus BICSecondary:• To compare progression-free survival (PFS)• To compare disease control rate (DCR, defined asthe percentage…
To assess the safety, tolerability, pharmacodynamics and efficacy of two DLQ02 topical formulations in patients with plaque psoriasis. To assess systemic exposure of CsA and F6H8 after topical application.